The Continuing Plague of Extended-spectrum β-lactamase–producing Enterobacteriaceae Infections

Infectious Disease Clinics of North America

Volumn 30, Issue 2, 2016, Pages 347-375

  Adler, Amos ^a,b   Katz, David E ^c   Marchaim, Dror ^b,d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c HEBREW UNIVERSITY   (Israel)

^d ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Escherichia coli; Gram negative; Klebsiella pneumoniae; MDROs; Proteus mirabilis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CLAVULANIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CLONAL VARIATION; DIABETES MELLITUS; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; HUMAN; INFECTION RISK; NONHUMAN; PHYLOGENY; PREVALENCE; REVIEW; SEX DIFFERENCE; URINARY TRACT INFECTION; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; INAPPROPRIATE PRESCRIBING; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; INAPPROPRIATE PRESCRIBING;

EID: 84991372921     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2016.02.003     Document Type: Review

References (237)

1. 1 Boucher, H.W., Talbot, G.H., Bradley, J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1 (2009), 1–12.
2. 2 Livermore, D.M., Has the era of untreatable infections arrived?. J Antimicrob Chemother 64:Suppl 1 (2009), i29–i36.
3. 3 Marchaim, D., Perez, F., Lee, J., et al. “Swimming in resistance”: co-colonization with carbapenem-resistant enterobacteriaceae and Acinetobacter baumannii or pseudomonas aeruginosa. Am J Infect Control 40:9 (2012), 830–835.
4. 4 Cohen-Nahum, K., Saidel-Odes, L., Riesenberg, K., et al. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 38:1 (2010), 41–46.
5. 5 Endimiani, A., Luzzaro, F., Brigante, G., et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 49:7 (2005), 2598–2605.
6. 6 Marchaim, D., Zaidenstein, R., Lazarovitch, T., et al. Epidemiology of bacteremia episodes in a single center: increase in gram-negative isolates, antibiotics resistance, and patient age. Eur J Clin Microbiol Infect Dis 27:11 (2008), 1045–1051.
7. 7 Bogan, C., Marchaim, D., The role of antimicrobial stewardship in curbing carbapenem resistance. Future Microbiol 8:8 (2013), 979–991.
8. 8 Tal Jasper, R., Coyle, J.R., Katz, D.E., et al. The complex epidemiology of extended-spectrum beta-lactamase-producing enterobacteriaceae. Future Microbiol 10 (2015), 819–839.
9. 9 Bonomo, R.A., Rossolini, G.M., Importance of antibiotic resistance and resistance mechanisms. Foreword. Expert Rev Anti Infect Ther 6:5 (2008), 549–550.
10. 10 Paterson, D.L., Bonomo, R.A., Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:4 (2005), 657–686.
11. 11 Peterson, L.R., Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect 14:Suppl 1 (2008), 181–184.
12. 12 Bush, K., Fisher, J.F., Epidemiological expansion, structural studies, and clinical challenges of new beta-lactamases from gram-negative bacteria. Annu Rev Microbiol 65 (2011), 455–478.
13. 13 Gerber, J.S., Kronman, M.P., Ross, R.K., et al. Identifying targets for antimicrobial stewardship in children's hospitals. Infect Control Hosp Epidemiol 34:12 (2013), 1252–1258.
14. 14 Peleg, A.Y., Hooper, D.C., Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362:19 (2010), 1804–1813.
15. 15 Collins, V.L., Marchaim, D., Pogue, J.M., et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 56:4 (2012), 2173–2177.
16. 16 Abraham, E.P., Chain, E., An enzyme from bacteria able to destroy penicillin. 1940. Rev Infect Dis 10:4 (1988), 677–678.
17. 17 Bradford, P.A., Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:4 (2001), 933–951 table of contents.
18. 18 Medeiros, A.A., Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 24:Suppl 1 (1997), S19–S45.
19. 19 Jacoby, G.A., Munoz-Price, L.S., The new beta-lactamases. N Engl J Med 352:4 (2005), 380–391.
20. 20 Bush, K., Jacoby, G.A., Medeiros, A.A., A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:6 (1995), 1211–1233.
21. 21 Jacoby, G.A., Bush, K., Beta-lactamase nomenclature. J Clin Microbiol, 43(12), 2005, 6220.
22. 22 Chopra, T., Marchaim, D., Veltman, J., et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 56:7 (2012), 3936–3942.
23. 23 Marchaim, D., Sunkara, B., Lephart, P.R., et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 33:8 (2012), 853–855.
24. 24 Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, (eds.) Nineteenth informational supplement. Approved standard m100–s19, 2009, Clinical and Laboratory Standards Institute, Wayne (PA).
25. 25 Endimiani, A., Paterson, D.L., Optimizing therapy for infections caused by enterobacteriaceae producing extended-spectrum beta-lactamases. Semin Respir Crit Care Med 28:6 (2007), 646–655.
26. 26 Marchaim, D., Lazarovitch, Z., Efrati, S., et al. Serious consequences to the use of cephalosporins as the first line of antimicrobial therapy administered in hemodialysis units. Nephron Clin Pract 101:2 (2005), c58–c64.
27. 27 Ben-Ami, R., Schwaber, M.J., Navon-Venezia, S., et al. Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis 42:7 (2006), 925–934.
28. 28 Pitout, J.D., Laupland, K.B., Extended-spectrum beta-lactamase-producing enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 8:3 (2008), 159–166.
29. 29 Pogue, J.M., Marchaim, D., Abreu-Lanfranco, O., et al. Fosfomycin activity versus carbapenem-resistant enterobacteriaceae and vancomycin-resistant enterococcus, Detroit, 2008-10. J Antibiot (Tokyo) 66:10 (2013), 625–627.
30. 30 Marchaim, D., Gottesman, T., Schwartz, O., et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 54:12 (2010), 5099–5104.
31. 31 Reinert, R.R., Low, D.E., Rossi, F., et al. Antimicrobial susceptibility among organisms from the Asia/Pacific rim, Europe and Latin and North America collected as part of test and the in vitro activity of tigecycline. J Antimicrob Chemother 60:5 (2007), 1018–1029.
32. 32 Nagy, E., Dowzicky, M.J., In vitro activity of tigecycline and comparators against a European compilation of anaerobes collected as part of the tigecycline evaluation and surveillance trial (test). Scand J Infect Dis 42:1 (2010), 33–38.
33. 33 Jones, R.N., Biedenbach, D.J., Gales, A.C., Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. And ESBL-producing Klebsiella spp.: report from the sentry antimicrobial surveillance program (USA, 1997-2000). Int J Antimicrob Agents 21:1 (2003), 1–7.
34. 34 Bouchillon, S.K., Iredell, J.R., Barkham, T., et al. Comparative in vitro activity of tigecycline and other antimicrobials against gram-negative and gram-positive organisms collected from the asia-pacific rim as part of the tigecycline evaluation and surveillance trial (test). Int J Antimicrob Agents 33:2 (2009), 130–136.
35. 35 Rodloff, A.C., Leclercq, R., Debbia, E.A., et al. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin Microbiol Infect 14:4 (2008), 307–314.
36. 36 Hoban, D.J., Bouchillon, S.K., Johnson, B.M., et al. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (test program, 2004). Diagn Microbiol Infect Dis 52:3 (2005), 215–227.
37. 37 Badura, A., Feierl, G., Pregartner, G., et al. Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in southeast Austria, 1998-2013. Clin Microbiol Infect 21:6 (2015), 569.e1–569.e7.
38. 38 Calbo, E., Garau, J., The changing epidemiology of hospital outbreaks due to ESBL-producing Klebsiella pneumoniae: the ctx-m-15 type consolidation. Future Microbiol 10 (2015), 1063–1075.
39. 39 Leibman, V., Martin, E.T., Tal-Jasper, R., et al. Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant enterobacteriaceae. Ann Clin Microbiol Antimicrob, 14, 2015, 31.
40. 40 Livermore, D.M., Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 27:2 (2012), 128–142.
41. 41 Livermore, D.M., Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect 14:Suppl 1 (2008), 3–10.
42. 42 Dellit, T.H., Owens, R.C., McGowan, J.E. Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:2 (2007), 159–177.
43. 43 del Rio, M.A., Chrane, D., Shelton, S., et al. Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children. Lancet 1:8336 (1983), 1241–1244.
44. 44 Bernstein Hahn, L., Barclay, C.A., Iribarren, M.A., et al. Ceftriaxone, a new parenteral cephalosporin, in the treatment of urinary tract infections. Chemotherapy 27:Suppl 1 (1981), 75–79.
45. 45 Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The international antimicrobial therapy cooperative group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 119:7 Pt 1 (1993), 584–593.
46. 46 Kliebe, C., Nies, B.A., Meyer, J.F., et al. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 28:2 (1985), 302–307.
47. 47 Bush, K., Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 14:Suppl 1 (2008), 134–143.
48. 48 Falagas, M.E., Karageorgopoulos, D.E., Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 73:4 (2009), 345–354.
49. 49 Brun-Buisson, C., Legrand, P., Philippon, A., et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 2:8554 (1987), 302–306.
50. 50 Babini, G.S., Livermore, D.M., Antimicrobial resistance amongst Klebsiella spp. Collected from intensive care units in southern and western Europe in 1997-1998. J Antimicrob Chemother 45:2 (2000), 183–189.
51. 51 Livermore, D.M., Yuan, M., Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. From intensive care units in Europe. J Antimicrob Chemother 38:3 (1996), 409–424.
52. 52 Decre, D., Gachot, B., Lucet, J.C., et al. Clinical and bacteriologic epidemiology of extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit. Clin Infect Dis 27:4 (1998), 834–844.
53. 53 Pitout, J.D., Nordmann, P., Laupland, K.B., et al. Emergence of enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:1 (2005), 52–59.
54. 54 Canton, R., Coque, T.M., The ctx-m beta-lactamase pandemic. Curr Opin Microbiol 9:5 (2006), 466–475.
55. 55 Hobson, R.P., MacKenzie, F.M., Gould, I.M., An outbreak of multiply-resistant Klebsiella pneumoniae in the Grampian region of Scotland. J Hosp Infect 33:4 (1996), 249–262.
56. 56 Borer, A., Gilad, J., Menashe, G., et al. Extended-spectrum beta-lactamase-producing enterobacteriaceae strains in community-acquired bacteremia in southern Israel. Med Sci Monit 8:1 (2002), CR44–CR47.
57. 57 Goldstein, F.W., Pean, Y., Gertner, J., Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The vigil'roc study group. Antimicrob Agents Chemother 39:11 (1995), 2516–2519.
58. 58 Blomberg, B., Jureen, R., Manji, K.P., et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 43:2 (2005), 745–749.
59. 59 Mirelis, B., Navarro, F., Miro, E., et al. Community transmission of extended-spectrum beta-lactamase. Emerg Infect Dis 9:8 (2003), 1024–1025.
60. 60 Pitout, J.D., Hanson, N.D., Church, D.L., et al. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blactx-m genes. Clin Infect Dis 38:12 (2004), 1736–1741.
61. 61 Woodford, N., Kaufmann, M.E., Karisik, E., et al. Molecular epidemiology of multiresistant Escherichia coli isolates from community-onset urinary tract infections in Cornwall, England. J Antimicrob Chemother 59:1 (2007), 106–109.
62. 62 Cormican, M., Morris, D., Corbett-Feeeney, G., et al. Extended spectrum beta-lactamase production and fluorquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis 32:4 (1998), 317–319.
63. 63 Goldstein, F.W., Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Multicentre study group. Eur J Clin Microbiol Infect Dis 19:2 (2000), 112–117.
64. 64 Centers for Disease Control and Prevention (CDC), Laboratory capacity to detect antimicrobial resistance, 1998. MMWR Morb Mortal Wkly Rep 48:51–52 (2000), 1167–1171.
65. 65 Munoz-Price, L.S., Long-term acute care hospitals. Clin Infect Dis 49:3 (2009), 438–443.
66. 66 Denman, S.J., Burton, J.R., Fluid intake and urinary tract infection in the elderly. JAMA 267:16 (1992), 2245–2249.
67. 67 de Medina, T., Carmeli, Y., The pivotal role of long-term care facilities in the epidemiology of Acinetobacter baumannii: another brick in the wall. Clin Infect Dis 50:12 (2010), 1617–1618.
68. 68 Marchaim, D., Chopra, T., Bogan, C., et al. The burden of multidrug-resistant organisms on tertiary hospitals posed by patients with recent stays in long-term acute care facilities. Am J Infect Control 40:8 (2012), 760–765.
69. 69 Adler, A., Gniadkowski, M., Baraniak, A., et al. Transmission dynamics of ESBL-producing Escherichia coli clones in rehabilitation wards at a tertiary care centre. Clin Microbiol Infect 18:12 (2012), E497–E505.
70. 70 Sengstock, D.M., Thyagarajan, R., Apalara, J., et al. Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 50:12 (2010), 1611–1616.
71. 71 Ben-Ami, R., Rodriguez-Bano, J., Arslan, H., et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 49:5 (2009), 682–690.
72. 72 Rodriguez-Bano, J., Alcala, J.C., Cisneros, J.M., et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 168:17 (2008), 1897–1902.
73. 73 Rodriguez-Bano, J., Lopez-Cerero, L., Navarro, M.D., et al. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 62:5 (2008), 1142–1149.
74. 74 Rodriguez-Bano, J., Paterson, D.L., A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms. Clin Infect Dis 42:7 (2006), 935–937.
75. 75 Doi, Y., Park, Y.S., Rivera, J.I., et al. Community-associated extended-spectrum beta-lactamase-producing Escherichia coli infection in the united states. Clin Infect Dis 56:5 (2013), 641–648.
76. 76 Hayakawa, K., Gattu, S., Marchaim, D., et al. Epidemiology and risk factors for isolation of Escherichia coli producing ctx-m-type extended-spectrum beta-lactamase in a large U.S. Medical center. Antimicrob Agents Chemother 57:8 (2013), 4010–4018.
77. 77 Wright, G.D., The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol 5:3 (2007), 175–186.
78. 78 Rodriguez-Bano, J., Navarro, M.D., Romero, L., et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Clin Microbiol Infect 14:2 (2008), 180–183.
79. 79 Schwaber, M.J., Navon-Venezia, S., Kaye, K.S., et al. Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 50:4 (2006), 1257–1262.
80. 80 Schwaber, M.J., Navon-Venezia, S., Schwartz, D., et al. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 49:5 (2005), 2137–2139.
81. 81 Schwaber, M.J., Carmeli, Y., Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 60:5 (2007), 913–920.
82. 82 Apisarnthanarak, A., Kiratisin, P., Mundy, L.M., Clinical and molecular epidemiology of healthcare-associated infections due to extended-spectrum beta-lactamase (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae that harbor multiple ESBL genes. Infect Control Hosp Epidemiol 29:11 (2008), 1026–1034.
83. 83 Doi, Y., Adams-Haduch, J.M., Paterson, D.L., Escherichia coli isolate coproducing 16s rRNA methylase and ctx-m-type extended-spectrum beta-lactamase isolated from an outpatient in the united states. Antimicrob Agents Chemother 52:3 (2008), 1204–1205.
84. 84 Doi, Y., Adams-Haduch, J.M., Shivannavar, C.T., et al. Faecal carriage of ctx-m-15-producing Klebsiella pneumoniae in patients with acute gastroenteritis. Indian J Med Res 129:5 (2009), 599–602.
85. 85 Doi, Y., Paterson, D.L., Egea, P., et al. Extended-spectrum and cmy-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 16:1 (2010), 33–38.
86. 86 Livermore, D.M., Hawkey, P.M., Ctx-m: changing the face of ESBLs in the UK. J Antimicrob Chemother 56:3 (2005), 451–454.
87. 87 Livermore, D.M., Hope, R., Reynolds, R., et al. Declining cephalosporin and fluoroquinolone non-susceptibility among bloodstream enterobacteriaceae from the UK: links to prescribing change?. J Antimicrob Chemother 68:11 (2013), 2667–2674.
88. 88 Paterson, D.L., Extended-spectrum beta-lactamases: the European experience. Curr Opin Infect Dis 14:6 (2001), 697–701.
89. 89 Poirel, L., Nordmann, P., Ducroz, S., et al. Extended-spectrum beta-lactamase ctx-m-15-producing Klebsiella pneumoniae of sequence type st274 in companion animals. Antimicrob Agents Chemother 57:5 (2013), 2372–2375.
90. 90 Arpin, C., Quentin, C., Grobost, F., et al. Nationwide survey of extended-spectrum {beta}-lactamase-producing enterobacteriaceae in the French community setting. J Antimicrob Chemother 63:6 (2009), 1205–1214.
91. 91 Djamdjian, L., Naas, T., Tande, D., et al. Ctx-m-93, a ctx-m variant lacking penicillin hydrolytic activity. Antimicrob Agents Chemother 55:5 (2011), 1861–1866.
92. 92 Bauernfeind, A., Grimm, H., Schweighart, S., A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 18:5 (1990), 294–298.
93. 93 Canton, R., Gonzalez-Alba, J.M., Galan, J.C., Ctx-m enzymes: origin and diffusion. Front Microbiol, 3, 2012, 110.
94. 94 Bonnet, R., Growing group of extended-spectrum beta-lactamases: the ctx-m enzymes. Antimicrob Agents Chemother 48:1 (2004), 1–14.
95. 95 Navon-Venezia, S., Chmelnitsky, I., Leavitt, A., et al. Dissemination of the ctx-m-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme ctx-m-41 in Proteus mirabilis in Israel. J Antimicrob Chemother 62:2 (2008), 289–295.
96. 96 Lytsy, B., Lindback, J., Torell, E., et al. A case-control study of risk factors for urinary acquisition of Klebsiella pneumoniae producing ctx-m-15 in an outbreak situation in Sweden. Scand J Infect Dis 42:6–7 (2010), 439–444.
97. 97 Azap, O.K., Arslan, H., Serefhanoglu, K., et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 16:2 (2010), 147–151.
98. 98 Apisarnthanarak, A., Kiratisin, P., Saifon, P., et al. Clinical and molecular epidemiology of community-onset, extended-spectrum beta-lactamase-producing Escherichia coli infections in Thailand: a case-case-control study. Am J Infect Control 35:9 (2007), 606–612.
99. 99 Calbo, E., Romani, V., Xercavins, M., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 57:4 (2006), 780–783.
100. 100 Rodriguez-Bano, J., Navarro, M.D., Romero, L., et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control. Clin Infect Dis 42:1 (2006), 37–45.
101. 101 Association AU. Best practice policy statement on urologic surgery antimicrobial prophylaxis. 2011.
102. 102 Urology EAo. Guidelines on urological infections; 2013.
103. 103 Lo, E., Nicolle, L., Classen, D., et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. Infect Control Hosp Epidemiol 29:Suppl 1 (2008), S41–S50.
104. 104 Wolf, J.S. Jr., Bennett, C.J., Dmochowski, R.R., et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 179:4 (2008), 1379–1390.
105. 105 Grabe, M., Botto, H., Cek, M., et al. Preoperative assessment of the patient and risk factors for infectious complications and tentative classification of surgical field contamination of urological procedures. World J Urol 30:1 (2012), 39–50.
106. 106 Botelho, L.A., Kraychete, G.B., Costa, E.S.J.L., et al. Widespread distribution of ctx-m and plasmid-mediated AmpC beta-lactamases in Escherichia coli from Brazilian chicken meat. Mem Inst Oswaldo Cruz 110:2 (2015), 249–254.
107. 107 Nagy, B., Szmolka, A., Smole Mozina, S., et al. Virulence and antimicrobial resistance determinants of verotoxigenic Escherichia coli (VTEC) and of multidrug-resistant E. Coli from foods of animal origin illegally imported to the EU by flight passengers. Int J Food Microbiol 209 (2015), 52–59.
108. 108 Wong, M.H., Liu, L., Yan, M., et al. Dissemination of inci2 plasmids that harbor the blactx-m element among clinical salmonella isolates. Antimicrob Agents Chemother 59:8 (2015), 5026–5028.
109. 109 Xi, M., Wu, Q., Wang, X., et al. Characterization of extended-spectrum beta-lactamase-producing Escherichia coli strains isolated from retail foods in Shaanxi Province, China. J Food Prot 78:5 (2015), 1018–1023.
110. 110 Capita, R., Alonso-Calleja, C., Antibiotic-resistant bacteria: a challenge for the food industry. Crit Rev Food Sci Nutr 53:1 (2013), 11–48.
111. 111 Koluman, A., Dikici, A., Antimicrobial resistance of emerging foodborne pathogens: status quo and global trends. Crit Rev Microbiol 39:1 (2013), 57–69.
112. 112 US supermarkets redefine antibiotic misuse. Lancet Infect Dis, 9(5), 2009, 265.
113. 113 Endimiani, A., Bertschy, I., Perreten, V., Escherichia coli producing cmy-2 beta-lactamase in bovine mastitis milk. J Food Prot 75:1 (2012), 137–138.
114. 114 Bortolaia, V., Guardabassi, L., Trevisani, M., et al. High diversity of extended-spectrum beta-lactamases in Escherichia coli isolates from Italian broiler flocks. Antimicrob Agents Chemother 54:4 (2010), 1623–1626.
115. 115 Kluytmans, J.A., Overdevest, I.T., Willemsen, I., et al. Extended-spectrum beta-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors. Clin Infect Dis 56:4 (2013), 478–487.
116. 116 Huijbers, P.M., de Kraker, M., Graat, E.A., et al. Prevalence of extended-spectrum beta-lactamase-producing enterobacteriaceae in humans living in municipalities with high and low broiler density. Clin Microbiol Infect 19:6 (2013), E256–E259.
117. 117 Leverstein-van Hall, M.A., Dierikx, C.M., Cohen Stuart, J., et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 17:6 (2011), 873–880.
118. 118 Jensen, L.B., Hasman, H., Agerso, Y., et al. First description of an oxyimino-cephalosporin-resistant, ESBL-carrying Escherichia coli isolated from meat sold in Denmark. J Antimicrob Chemother 57:4 (2006), 793–794.
119. 119 Politi, L., Tassios, P.T., Lambiri, M., et al. Repeated occurrence of diverse extended-spectrum beta-lactamases in minor serotypes of food-borne salmonella enterica subsp. enterica. J Clin Microbiol 43:7 (2005), 3453–3456.
120. 120 Leistner, R., Meyer, E., Gastmeier, P., et al. Risk factors associated with the community-acquired colonization of extended-spectrum beta-lactamase (ESBL) positive Escherichia coli. An exploratory case-control study. PLoS One, 8(9), 2013, e74323.
121. 121 Jourdan-da Silva, N., Watrin, M., Weill, F.X., et al. Outbreak of haemolytic uraemic syndrome due to shiga toxin-producing Escherichia coli o104:H4 among French tourists returning from turkey, September 2011. Euro Surveill, 17(4), 2012.
122. 122 Ullrich, S., Bremer, P., Neumann-Grutzeck, C., et al. Symptoms and clinical course of EHEC o104 infection in hospitalized patients: a prospective single center study. PLoS One, 8(2), 2013, e55278.
123. 123 Aurass, P., Prager, R., Flieger, A., EHEC/EAEC o104:H4 strain linked with the 2011 German outbreak of haemolytic uremic syndrome enters into the viable but non-culturable state in response to various stresses and resuscitates upon stress relief. Environ Microbiol 13:12 (2011), 3139–3148.
124. 124 Costa, D., Vinue, L., Poeta, P., et al. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli isolates in faecal samples of broilers. Vet Microbiol 138:3–4 (2009), 339–344.
125. 125 Guenther, S., Aschenbrenner, K., Stamm, I., et al. Comparable high rates of extended-spectrum-beta-lactamase-producing Escherichia coli in birds of prey from Germany and Mongolia. PLoS One, 7(12), 2012, e53039.
126. 126 Guenther, S., Bethe, A., Fruth, A., et al. Frequent combination of antimicrobial multiresistance and extraintestinal pathogenicity in Escherichia coli isolates from urban rats (Rattus norvegicus) in Berlin, Germany. PLoS One, 7(11), 2012, e50331.
127. 127 Guenther, S., Grobbel, M., Beutlich, J., et al. Ctx-m-15-type extended-spectrum beta-lactamases-producing Escherichia coli from wild birds in Germany. Environ Microbiol Rep 2:5 (2010), 641–645.
128. 128 Hiroi, M., Yamazaki, F., Harada, T., et al. Prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in food-producing animals. J Vet Med Sci 74:2 (2012), 189–195.
129. 129 Liu, B.T., Yang, Q.E., Li, L., et al. Dissemination and characterization of plasmids carrying oqxab-bla ctx-m genes in Escherichia coli isolates from food-producing animals. PLoS One, 8(9), 2013, e73947.
130. 130 Hordijk, J., Schoormans, A., Kwakernaak, M., et al. High prevalence of fecal carriage of extended spectrum beta-lactamase/AmpC-producing enterobacteriaceae in cats and dogs. Front Microbiol, 4, 2013, 242.
131. 131 Dierikx, C., van Essen-Zandbergen, A., Veldman, K., et al. Increased detection of extended spectrum beta-lactamase producing salmonella enterica and Escherichia coli isolates from poultry. Vet Microbiol 145:3–4 (2010), 273–278.
132. 132 Overdevest, I., Willemsen, I., Rijnsburger, M., et al. Extended-spectrum beta-lactamase genes of Escherichia coli in chicken meat and humans, the Netherlands. Emerg Infect Dis 17:7 (2011), 1216–1222.
133. 133 Wassenberg, M.W., Bootsma, M.C., Troelstra, A., et al. Transmissibility of livestock-associated methicillin-resistant staphylococcus aureus (st398) in Dutch hospitals. Clin Microbiol Infect 17:2 (2011), 316–319.
134. 134 Laupland, K.B., Church, D.L., Vidakovich, J., et al. Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 57:6 (2008), 441–448.
135. 135 Lewis, J.S. 2nd, Herrera, M., Wickes, B., et al. First report of the emergence of ctx-m-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Antimicrob Agents Chemother 51:11 (2007), 4015–4021.
136. 136 Moland, E.S., Black, J.A., Hossain, A., et al. Discovery of ctx-m-like extended-spectrum beta-lactamases in Escherichia coli isolates from five US states. Antimicrob Agents Chemother 47:7 (2003), 2382–2383.
137. 137 Nicolas-Chanoine, M.H., Blanco, J., Leflon-Guibout, V., et al. Intercontinental emergence of Escherichia coli clone o25:H4-st131 producing ctx-m-15. J Antimicrob Chemother 61:2 (2008), 273–281.
138. 138 Coque, T.M., Novais, A., Carattoli, A., et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase ctx-m-15. Emerg Infect Dis 14:2 (2008), 195–200.
139. 139 Rodriguez-Bano, J., Picon, E., Gijon, P., et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 50:1 (2010), 40–48.
140. 140 Cagnacci, S., Gualco, L., Debbia, E., et al. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups o25:H4-st 131 and o15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 46:8 (2008), 2605–2612.
141. 141 Lau, S.H., Reddy, S., Cheesbrough, J., et al. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. J Clin Microbiol 46:3 (2008), 1076–1080.
142. 142 Dahbi, G., Mora, A., Lopez, C., et al. Emergence of new variants of st131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum beta-lactamases. Int J Antimicrob Agents 42:4 (2013), 347–351.
143. 143 Peirano, G., Pitout, J.D., Molecular epidemiology of Escherichia coli producing ctx-m beta-lactamases: the worldwide emergence of clone st131 o25:H4. Int J Antimicrob Agents 35:4 (2010), 316–321.
144. 144 Clermont, O., Bonacorsi, S., Bingen, E., Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 66:10 (2000), 4555–4558.
145. 145 Clermont, O., Johnson, J.R., Menard, M., et al. Determination of Escherichia coli o types by allele-specific polymerase chain reaction: application to the o types involved in human septicemia. Diagn Microbiol Infect Dis 57:2 (2007), 129–136.
146. 146 Pitout, J.D., Gregson, D.B., Campbell, L., et al. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary health region from 2000 to 2007: emergence of clone st131 as a cause of community-acquired infections. Antimicrob Agents Chemother 53:7 (2009), 2846–2851.
147. 147 Rogers, B.A., Sidjabat, H.E., Paterson, D.L., Escherichia coli o25b-st131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 66:1 (2011), 1–14.
148. 148 Petty, N.K., Ben Zakour, N.L., Stanton-Cook, M., et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A 111:15 (2014), 5694–5699.
149. 149 Lopez-Cerero, L., Navarro, M.D., Bellido, M., et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group o25b/st131: risk factors and clinical implications. J Antimicrob Chemother 69:3 (2014), 809–814.
150. 150 Sherchan, J.B., Hayakawa, K., Miyoshi-Akiyama, T., et al. Clinical epidemiology and molecular analysis of extended-spectrum-beta-lactamase-producing Escherichia coli in Nepal: characteristics of sequence types 131 and 648. Antimicrob Agents Chemother 59:6 (2015), 3424–3432.
151. 151 Rattinger, G.B., Mullins, C.D., Zuckerman, I.H., et al. A sustainable strategy to prevent misuse of antibiotics for acute respiratory infections. PLoS One, 7(12), 2012, e51147.
152. 152 Harris, A.D., Kotetishvili, M., Shurland, S., et al. How important is patient-to-patient transmission in extended-spectrum beta-lactamase Escherichia coli acquisition. Am J Infect Control 35:2 (2007), 97–101.
153. 153 Arpin, C., Dubois, V., Coulange, L., et al. Extended-spectrum beta-lactamase-producing enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 47:11 (2003), 3506–3514.
154. 154 Arpin, C., Dubois, V., Maugein, J., et al. Clinical and molecular analysis of extended-spectrum {beta}-lactamase-producing Enterobacteria in the community setting. J Clin Microbiol 43:10 (2005), 5048–5054.
155. 155 Rodriguez-Bano, J., Navarro, M.D., Romero, L., et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:3 (2004), 1089–1094.
156. 156 Banerjee, R., Strahilevitz, J., Johnson, J.R., et al. Predictors and molecular epidemiology of community-onset extended-spectrum beta-lactamase-producing Escherichia coli infection in a Midwestern community. Infect Control Hosp Epidemiol 34:9 (2013), 947–953.
157. 157 Soraas, A., Sundsfjord, A., Sandven, I., et al. Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae–a case-control study in a low prevalence country. PLoS One, 8(7), 2013, e69581.
158. 158 Freeman, J.T., Williamson, D.A., Heffernan, H., et al. Comparative epidemiology of ctx-m-14 and ctx-m-15 producing Escherichia coli: association with distinct demographic groups in the community in New Zealand. Eur J Clin Microbiol Infect Dis 31:8 (2012), 2057–2060.
159. 159 Valverde, A., Grill, F., Coque, T.M., et al. High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 46:8 (2008), 2796–2799.
160. 160 Skippen, I., Shemko, M., Turton, J., et al. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp.: a nested case-control study from a tertiary hospital in London. J Hosp Infect 64:2 (2006), 115–123.
161. 161 Pena, C., Gudiol, C., Tubau, F., et al. Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 12:3 (2006), 279–284.
162. 162 Graffunder, E.M., Preston, K.E., Evans, A.M., et al. Risk factors associated with extended-spectrum beta-lactamase-producing organisms at a tertiary care hospital. J Antimicrob Chemother 56:1 (2005), 139–145.
163. 163 Friedman, N.D., Kaye, K.S., Stout, J.E., et al. Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 137:10 (2002), 791–797.
164. 164 Bratzler, D.W., Dellinger, E.P., Olsen, K.M., et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 14:1 (2013), 73–156.
165. 165 Martin, E.T., Tansek, R., Collins, V., et al. The carbapenem-resistant enterobacteriaceae score: a bedside score to rule out infection with carbapenem-resistant enterobacteriaceae among hospitalized patients. Am J Infect Control 41:2 (2013), 180–182.
166. 166 Marchaim, D., Chopra, T., Bhargava, A., et al. Recent exposure to antimicrobials and carbapenem-resistant enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 33:8 (2012), 817–830.
167. 167 Abbo, A., Carmeli, Y., Navon-Venezia, S., et al. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 26:11 (2007), 793–800.
168. 168 Cosgrove, S.E., Sakoulas, G., Perencevich, E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:1 (2003), 53–59.
169. 169 Aloush, V., Navon-Venezia, S., Seigman-Igra, Y., et al. Multidrug-resistant pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50:1 (2006), 43–48.
170. 170 Carmeli, Y., Samore, M.H., Huskins, C., The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch Intern Med 159:20 (1999), 2461–2468.
171. 171 Bogan, C., Kaye, K.S., Chopra, T., et al. Outcomes of carbapenem-resistant enterobacteriaceae isolation: matched analysis. Am J Infect Control 42:6 (2014), 612–620.
172. 172 Melzer, M., Eykyn, S.J., Gransden, W.R., et al. Is methicillin-resistant staphylococcus aureus more virulent than methicillin-susceptible s. Aureus? a comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 37:11 (2003), 1453–1460.
173. 173 Sahly, H., Navon-Venezia, S., Roesler, L., et al. Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae. Antimicrob Agents Chemother 52:9 (2008), 3029–3034.
174. 174 Rodriguez-Bano, J., Mingorance, J., Fernandez-Romero, N., et al. Outcome of bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli: impact of microbiological determinants. J Infect 67:1 (2013), 27–34.
175. 175 Park, Y.S., Adams-Haduch, J.M., Shutt, K.A., et al. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother 56:4 (2012), 1870–1876.
176. 176 Sidjabat, H.E., Paterson, D.L., Adams-Haduch, J.M., et al. Molecular epidemiology of ctx-m-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother 53:11 (2009), 4733–4739.
177. 177 Doi, Y., Adams, J., O'Keefe, A., et al. Community-acquired extended-spectrum beta-lactamase producers, united states. Emerg Infect Dis 13:7 (2007), 1121–1123.
178. 178 Harris, A.D., Control group selection is an important but neglected issue in studies of antibiotic resistance. Ann Intern Med, 132(11), 2000, 925.
179. 179 Kaye, K.S., Harris, A.D., Samore, M., et al. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 26:4 (2005), 346–351.
180. 180 Rodriguez-Bano, J., Pascual, A., Clinical significance of extended-spectrum beta-lactamases. Expert Rev Anti Infect Ther 6:5 (2008), 671–683.
181. 181 Tumbarello, M., Sanguinetti, M., Montuori, E., et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 51:6 (2007), 1987–1994.
182. 182 Tumbarello, M., Spanu, T., Sanguinetti, M., et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 50:2 (2006), 498–504.
183. 183 Paul, M., Shani, V., Muchtar, E., et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 54:11 (2010), 4851–4863.
184. 184 Kumar, A., Roberts, D., Wood, K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:6 (2006), 1589–1596.
185. 185 Tumbarello, M., Trecarichi, E.M., Bassetti, M., et al. Identifying patients harboring extended-spectrum-beta-lactamase-producing enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob Agents Chemother 55:7 (2011), 3485–3490.
186. 186 Naas, T., Cuzon, G., Truong, H., et al. Evaluation of a DNA microarray, the check-points ESBL/KPC array, for rapid detection of TEM, SHV, and ctx-m extended-spectrum beta-lactamases and KPC carbapenemases. Antimicrob Agents Chemother 54:8 (2010), 3086–3092.
187. 187 Oviano, M., Fernandez, B., Fernandez, A., et al. Rapid detection of enterobacteriaceae producing extended spectrum beta-lactamases directly from positive blood cultures by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Clin Microbiol Infect 20:11 (2014), 1146–1157.
188. 188 Johnson, S.W., Anderson, D.J., May, D.B., et al. Utility of a clinical risk factor scoring model in predicting infection with extended-spectrum beta-lactamase-producing enterobacteriaceae on hospital admission. Infect Control Hosp Epidemiol 34:4 (2013), 385–392.
189. 189 Vitkon-Barkay, I., Yekutiel, M., Martin, E.T., et al. Developing a score to shorten the time to initiation of appropriate therapy for extensively drug resistant gram-negative bacilli and avoid unnecessary use of polymixins. (ESCMID) ESoCMaID, (eds.), 2014, European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Barcelona (Spain).
190. 190 Paterson, D.L., Ko, W.C., Von Gottberg, A., et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 39:1 (2004), 31–37.
191. 191 Vardakas, K.Z., Tansarli, G.S., Rafailidis, P.I., et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 67:12 (2012), 2793–2803.
192. 192 Carmeli, Y., Lidji, S.K., Shabtai, E., et al. The effects of group 1 versus group 2 carbapenems on imipenem-resistant pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis 70:3 (2011), 367–372.
193. 193 Dellinger, R.P., Levy, M.M., Carlet, J.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36:1 (2008), 296–327.
194. 194 Gutierrez-Gutierrez, B., Bonomo, R.A., Carmeli, Y., et al. Ertapenem for the treatment of bloodstream infections due to esbl-producing enterobacteriaceae: A multinational pre-registered cohort study. J Antimicrob Chemother, 2016 [Epub ahead of print].
195. 195 Schwaber, M.J., Carmeli, Y., Carbapenem-resistant enterobacteriaceae: a potential threat. JAMA 300:24 (2008), 2911–2913.
196. 196 Schwaber, M.J., Lev, B., Israeli, A., et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 52:7 (2011), 848–855.
197. 197 Bin, C., Hui, W., Renyuan, Z., et al. Outcome of cephalosporin treatment of bacteremia due to ctx-m-type extended-spectrum beta-lactamase-producing Escherichia coli. Diagn Microbiol Infect Dis 56:4 (2006), 351–357.
198. 198 Paterson, D.L., Ko, W.C., Von Gottberg, A., et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 39:6 (2001), 2206–2212.
199. 199 Wong-Beringer, A., Hindler, J., Loeloff, M., et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 34:2 (2002), 135–146.
200. 200 Kang, C.I., Kim, S.H., Park, W.B., et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:12 (2004), 4574–4581.
201. 201 Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, (eds.) Nineteenth informational supplement. Approved standard m100–s20, 2010, Clinical and Laboratory Standards Institute, Wayne (PA).
202. 202 Livermore, D.M., Andrews, J.M., Hawkey, P.M., et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?. J Antimicrob Chemother 67:7 (2012), 1569–1577.
203. 203 Endimiani, A., Luzzaro, F., Perilli, M., et al. Bacteremia due to Klebsiella pneumoniae isolates producing the tem-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 38:2 (2004), 243–251.
204. 204 Rodriguez-Martinez, J.M., Diaz de Alba, P., Briales, A., et al. Contribution of oqxab efflux pumps to quinolone resistance in extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae. J Antimicrob Chemother 68:1 (2013), 68–73.
205. 205 Kritsotakis, E.I., Tsioutis, C., Roumbelaki, M., et al. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}-lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother 66:6 (2011), 1383–1391.
206. 206 Lee, C.H., Su, L.H., Tang, Y.F., et al. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. J Antimicrob Chemother 58:5 (2006), 1074–1077.
207. 207 Lopez-Cerero, L., Picon, E., Morillo, C., et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 16:2 (2010), 132–136.
208. 208 Thomson, K.S., Moland, E.S., Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother 45:12 (2001), 3548–3554.
209. 209 Zimhony, O., Chmelnitsky, I., Bardenstein, R., et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 50:9 (2006), 3179–3182.
210. 210 Rodriguez-Bano, J., Navarro, M.D., Retamar, P., et al. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 54:2 (2012), 167–174.
211. 211 Perez, F., Bonomo, R.A., Can we really use ss-lactam/ss-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producing bacteria?. Clin Infect Dis 54:2 (2012), 175–177.
212. 212 Dedeic-Ljubovic, A., Hukic, M., Pfeifer, Y., et al. Emergence of ctx-m-15 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in Bosnia and Herzegovina. Clin Microbiol Infect 16:2 (2010), 152–156.
213. 213 Pfundstein, J., Roghmann, M.C., Schwalbe, R.S., et al. A randomized trial of surgical antimicrobial prophylaxis with and without vancomycin in organ transplant patients. Clin Transplant 13:3 (1999), 245–252.
214. 214 Hall, J.C., Christiansen, K., Carter, M.J., et al. Antibiotic prophylaxis in cardiac operations. Ann Thorac Surg 56:4 (1993), 916–922.
215. 215 Tissera, S., Lee, S.M., Isolation of extended spectrum beta-lactamase (ESBL) producing bacteria from urban surface waters in Malaysia. Malays J Med Sci 20:3 (2013), 14–22.
216. 216 Ofer-Friedman, H., Shefler, C., Sharma, S., et al. Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing enterobacteriaceae. Infect Control Hosp Epidemiol 36:8 (2015), 981–985.
217. 217 Tamma, P.D., Han, J.H., Rock, C., et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia. Clin Infect Dis 60:9 (2015), 1319–1325.
218. 218 Lu, P.L., Liu, Y.C., Toh, H.S., et al. Epidemiology and antimicrobial susceptibility profiles of gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the study for monitoring antimicrobial resistance trends (SMART). Int J Antimicrob Agents 40:Suppl (2012), S37–S43.
219. 219 Hawser, S.P., Bouchillon, S.K., Lascols, C., et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum beta-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 18:3 (2012), 253–259.
220. 220 Hoban, D.J., Bouchillon, S.K., Hawser, S.P., et al. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the study for monitoring antimicrobial resistance trends (SMART). Antimicrob Agents Chemother 54:7 (2010), 3031–3034.
221. 221 Rotschafer, J.C., Zabinski, R.A., Walker, K.J., Pharmacodynamic factors of antibiotic efficacy. Pharmacotherapy 12:6 Pt 2 (1992), 64S–70S.
222. 222 Gupta, K., Hooton, T.M., Naber, K.G., et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:5 (2011), e103–e120.
223. 223 Pakyz, A.L., MacDougall, C., Oinonen, M., et al. Trends in antibacterial use in US academic health centers: 2002 to 2006. Arch Intern Med 168:20 (2008), 2254–2260.
224. 224 Klastersky, J., Thys, J.P., Mombelli, G., Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria. Rev Infect Dis 3:1 (1981), 74–83.
225. 225 Falagas, M.E., Maraki, S., Karageorgopoulos, D.E., et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 35:3 (2010), 240–243.
226. 226 FDA, Drug safety communication - increased risk of death with tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010, FDA.
227. 227 Pogue, J.M., Lee, J., Marchaim, D., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53:9 (2011), 879–884.
228. 228 Pogue, J.M., Cohen, D.A., Marchaim, D., Editorial commentary: polymyxin-resistant Acinetobacter baumannii: urgent action needed. Clin Infect Dis 60:9 (2015), 1304–1307.
229. 229 Chen, P.C., Chang, L.Y., Lu, C.Y., et al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J Microbiol Immunol Infect 47:6 (2014), 478–483.
230. 230 Kurtaran, B., Candevir, A., Tasova, Y., et al. Antibiotic resistance in community-acquired urinary tract infections: prevalence and risk factors. Med Sci Monit 16:5 (2010), CR246–CR251.
231. 231 Yamamoto, S., Higuchi, Y., Nojima, M., Current therapy of acute uncomplicated cystitis. Int J Urol 17:5 (2010), 450–456.
232. 232 Kim, M.E., Ha, U.S., Cho, Y.H., Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents 31:Suppl 1 (2008), S15–S18.
233. 233 Ilic, T., Gracan, S., Arapovic, A., et al. Changes in bacterial resistance patterns in children with urinary tract infections on antimicrobial prophylaxis at university hospital in split. Med Sci Monit 17:7 (2011), CR355–CR361.
234. 234 Lowe, C.F., McGeer, A., Muller, M.P., et al. Decreased susceptibility to noncarbapenem antimicrobials in extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates in Toronto, Canada. Antimicrob Agents Chemother 56:7 (2012), 3977–3980.
235. 235 Puerto, A.S., Fernandez, J.G., del Castillo Jde, D., et al. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of Escherichia coli. Diagn Microbiol Infect Dis 54:2 (2006), 135–139.
236. 236 de Cueto, M., Lopez, L., Hernandez, J.R., et al. In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 50:1 (2006), 368–370.
237. 237 Arslan, H., Azap, O.K., Ergonul, O., et al. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 56:5 (2005), 914–918.